Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 26 April 2017

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Noninvasive markers of liver fibrosis in drug users with Hep C

FibroSURE, alanine aminotransferase, and aminotransferase-to-platelet-ratio index tests predict insignificant fibrosis in injection drug users with Hep C, reports this month's Hepatology.

News image

fiogf49gjkf04

Most Hepatitis C virus infections are acquired by injection drug use.

Dr Lucy Wilson and colleagues from the USA assessed prospective data on the progression of liver fibrosis.

Baseline liver biopsies were obtained from 1996 to 1998 on a random sample of 210 out of 1667 Hepatitis C virus-positive injection drug users.

Subjects were followed biannually, with a second biopsy offered to those eligible.

Among 119 prospectively followed injection drug users, 96% were African American, and 97% were Hepatitis C virus genotype 1a/b.

A further 27% were HIV-infected, with a median age of 42 years.

Paired biopsies were scored from 0 to 6.

The research team defined significant fibrosis was as score 3 or greater.

Progression of fibrosis was defined as an increase 2 or more units or clinical evidence of end-stage liver disease.

The predictive value for alanine aminotransferase specificities was 73%
Hepatology

The team's predictive values of blood markers include FibroSURE, aspartate aminotransferase-to-platelet-ratio index and alanine aminotransferase.

The researchers assessed the detection of contemporaneous and future liver fibrosis.

The team noted that 91% did not have significant liver fibrosis at first biopsy.

The researchers' predictive value for detecting insignificant fibrosis at first biopsy was greater than 95% for FibroSURE.

The predictive value for aminotransferase-to-platelet-ratio index, and alanine aminotransferase specificities were 73%.

After 4 years median follow-up, 21% had progression of fibrosis.

The researchers observed that this was significantly associated with serum level of Hepatitis C virus RNA and alanine aminotransferase.

No serological test had a predictive value greater than 40% for contemporaneous or future significant fibrosis.

Initial biopsy result had only a 30% value for predicting future significant fibrosis.

Dr Wilson's team concluded, “Significant liver fibrosis and progression were detected in some, but not most, injection drug users in this cohort.”

“In this setting with low fibrosis prevalence, FibroSURE, alanine aminotransferase, and aminotransferase-to-platelet-ratio index tests predict insignificant fibrosis.”

“However, further work is needed to find noninvasive markers of significant liver fibrosis.”

Hepatol 2006: 43(4): 788-95
05 April 2006

Go to top of page Email this page Email this page to a colleague

 26 April 2017 
Iron formulations for anemia in IBD
 26 April 2017 
National gastric cancer screening program
 26 April 2017 
Time to colonoscopy and colorectal cancer
 25 April 2017 
Biologics for mucosal healing in IBD
 25 April 2017 
Telemedicine tool for IBD
 25 April 2017 
Asymptomatic carriers and C. diff
 24 April 2017 
Functional dyspepsia and duodenal eosinophilia
 24 April 2017 
Bacterial infections in cirrhosis 
 24 April 2017 
Poor oral health and IBD
 21 April 2017 
Improving adenoma detection rate
 21 April 2017 
Infection after living donor liver transplantation
 21 April 2017 
Treatment of abdominal pain in IBS 
 20 April 2017 
Diagnosis of small colorectal polyps
 20 April 2017 
Diagnosis of GERD
 20 April 2017 
Prediction of HCV vertical transmission
 19 April 2017 
Iron replacement therapy in IBD
 19 April 2017 
Heat stroke leading to acute liver failure
 19 April 2017 
Pregnancy and anti-TNF agents in IBD
 14 April 2017 
Water exchange and adenoma detection rate
 14 April 2017 
Survival in IBD associated colorectal cancer
 14 April 2017 
Tacrolimus for liver transplantation
 14 April 2017 
GastroHep.com Easter break
 13 April 2017 
Hepatic manifestations of IBD
 13 April 2017 
Multidisciplinary approach to pancreas cancer
 13 April 2017 
Predicting post-operative Crohn's recurrence
 12 April 2017 
Liver disease in patients for liver transplant
 12 April 2017 
Management of common bile duct stones
 12 April 2017 
Nucleotide analogues for Hep B and cancer risk
 11 April 2017 
Biodgradable stents and benign intestinal strictures
 11 April 2017 
Interferon-free regimens for HCV-related Child C cirrhosis
 11 April 2017 
Weight loss after nutrition training
 10 April 2017 
Polymorphisms associated with liver injury from statins
 10 April 2017 
Genetic risk factors in IBD infections
 10 April 2017 
Regimens for HCV-related Child C cirrhosis
 07 April 2017 
Transition readiness scores in adolescents with IBD
 07 April 2017 
IBD disability index
 07 April 2017 
Hepatocellular carcinoma risk in different etiologies of cirrhosis
 06 April 2017 
Antidepressants in IBD
 06 April 2017 
Meal fat content and reflux
 06 April 2017 
Hep C treatment transformation with direct antiviral agents
 05 April 2017 
Threatening life experiences in ulcerative colitis
 05 April 2017 
Prednisolone and mortality in alcoholic hepatitis 
 05 April 2017 
5-aminosalicylates and colorectal cancer in IBD
 04 April 2017 
Celiac disease in the elderly
 04 April 2017 
IBS after infectious enteritis
 04 April 2017 
Diarrhea after allogeneic stem cell transplantation
 03 April 2017 
Minorities at increased gastric cancer risk
 03 April 2017 
Incidence and risk factors of IBD
 03 April 2017 
Western diet and diverticulitis
 31 March 2017 
GI safety of direct oral anticoagulants
 31 March 2017 
Screening for celiac disease
 31 March 2017 
Low-FODMAP diet in patients with functional GI disorders
 30 March 2017 
Low-grade esophageal dysplasia and cancer risk
 30 March 2017 
Poor oral health and IBD
 30 March 2017 
Causes of villus atrophy in celiac disease without gluten
 29 March 2017 
Telemedicine in gastroenterology
 29 March 2017 
Red meat and pancreatic cancer risk
 29 March 2017 
Therapeutic goals in Crohn's and rheumatoid arthritis
 28 March 2017 
H. pylori infection in junior high school students
 28 March 2017 
BMI and laporoscopic colorectal surgery

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2017 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us